Dong-Ge Liu

Dong-Ge Liu

Auto-generated profile, based on publicly available information

Dong-Ge Liu

Beijing Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
ZWZheng Wang
Zheng Wang
GCGang Cheng
Gang Cheng
XHXiaohong Han
Xiaohong Han
XMXinlin Mu
Xinlin Mu
YZYuhui Zhang
Yuhui Zhang
DLDongge Liu
Dongge Liu

1 January 2016 in Chinese Journal of Cancer Research
Verified
Journal Article
Open access
ZWZheng Wang
Zheng Wang
XWXiaonan Wu
Xiaonan Wu
XHXiaohong Han
Xiaohong Han
GCGang Cheng
Gang Cheng
XMXinlin Mu
Xinlin Mu
YSYuan-kai Shi
Yuan-kai Shi
The relationship between anaplastic lymphoma kinase (ALK) expression in malignant pleural effusion (MPE) samples detected only by Ventana immunohistochemistry (IHC) ALK (D5F3) and the efficacy of ALK-tyrosine kinase inhibitor therapy is uncertain. Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody testing was performed on 313 cell blocks of MPE samples from Chinese patients with advanced lung adenocarcinoma, and fluorescence in situ hybridization (FISH) was used to verify the ALK gene status in Ventana IHC ALK (D5F3)-positive samples. The follow-up clinical data on patients who received crizotinib treatment were recorded. Of the 313 MPE samples, 27 (8.6%) were confirmed as ALK expression-positive, and the Ventana IHC ALK (D5F3)-positive rate was 17.3% (27/156) in wild-type epidermal growth factor receptor (EGFR) MPE samples. Twenty-three of the 27 IHC ALK (D5F3)-positive samples were positive by FISH. Of the 11 Ventana IHC ALK (D5F3)-positive patients who received crizotinib therapy, 2 patients had complete response (CR), 5 had partial response (PR) and 3 had stable disease (SD). The ALK gene expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma.


1 November 2015
Verified
Journal Article
Closed access
HWHua Wang
Hua Wang
FFFang Fang
Fang Fang
KCKe Chai
Ke Chai
YLYao Luo
Yao Luo
BLBing Liu
Bing Liu
JYJie-Fu Yang
Jie-Fu Yang

1 July 2014
Verified
Journal Article
Closed access
ZWZheng Wang
Zheng Wang
XWXiaonan Wu
Xiaonan Wu
YSYuan-kai Shi
Yuan-kai Shi
XHXiaohong Han
Xiaohong Han
GCGang Cheng
Gang Cheng
DLDongge Liu
Dongge Liu

1 March 2011
Verified
Journal Article
Closed access
CYChong-Qing Yang
Chong-Qing Yang
ZCZhuang Cui
Zhuang Cui
JYJing-Jing Yao
Jing-Jing Yao
DLDong-Ge Liu
Dong-Ge Liu